Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03387397 · ClinicalTrials.gov registry record

Assessing Differential Adherence to Medications and Quality of Life Among People Living With HIV and Comorbidities

A clinical trial, sponsored by Northwell Health.

Completed
Registry status
170
Enrollment target

NCT03387397: Completed study, sponsored by Northwell Health.

NCT03387397 is a clinical trial that has completed, run by Northwell Health. The registered enrollment target is 170 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03387397 has completed, sponsored by Northwell Health.

COMPLETED
Registry status
170 participants
Enrollment target

Study Summary

The investigators propose to utilize quantitative and qualitative methodology to better understand the impact of multiple drug use (polypharmacy) on medication adherence as well as the driving forces behind differential adherence in people living with HIV (PLWH) with comorbidities. Since the clinical relevance of differential adherence to antiretroviral therapy (ART) medication has already been demonstrated and associated with virologic failure and a more rapid progression to AIDS and death, it is imperative to understand the driving forces behind differential adherence (selective drug taking) and its impact on treatment outcomes in PLWH with comorbidities. To this end, the investigators propose utilizing self-report adherence data and abstracted medical record data including pharmacy refills to assess medication adherence among PLWH with comorbidities. The information gained regarding patients' clinical outcomes as well as patients' reported treatment adherence, quality of life, beliefs about medications, and treatment satisfaction will provide the investigators with a comprehensive picture of what constitutes successful HIV treatment among those PLWH managing multiple medications. This is particularly important as non-successful treatment may result in low patient satisfaction, breach of patient-provider trust and reduced medication adherence.

Primary Outcome

To measure medication adherence to ART the investigators will use the validated AIDS Clinical Trials Group (ACTG) Adherence Questionnaire. This assessment is considered one of the "gold-standard" ART self-reported adherence questionnaires. The questionnaire assesses the number of doses missed per medication per day over a recall period of the previous four days. Mean number of doses missed is calculated for all ART medications over the four days. A higher mean, indicates more doses missed.

Trial Details

FieldValue
Enrollment Target 170 participants
Start Date 2017-12-12
Est. Completion 2023-09-27
Northwell Health

370 total trials

What the finished NCT03387397 record still lists

NCT03387397 is an observational study that tracks outcomes without assigning an intervention. The registered 170 participants enrollment target is mid-sized for trials with a published cap.

The record links to 0 conditions, and to 0 interventions.

NCT03387397 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03387397 about?

NCT03387397 is a clinical study titled "Assessing Differential Adherence to Medications and Quality of Life Among People Living With HIV and Comorbidities". The investigators propose to utilize quantitative and qualitative methodology to better understand the impact of multiple drug use (polypharmacy) on medication adherence as well as the driving forces behind differential adherence in people living with HIV (PLWH) with comorbidities. Since the clinica...

What is the current status of trial NCT03387397?

This trial is currently completed. The enrollment target is 170 participants. The study started on 2017-12-12. Estimated completion is 2023-09-27.

Who is sponsoring clinical trial NCT03387397?

This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02016430 · 170 participants · NA

    Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)

  • NCT02621021 · 170 participants · Phase 2

    A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab

  • NCT04094701 · 170 participants · NA

    Hip Arthroscopy Postoperative Opioid Demands

  • NCT04166409 · 170 participants · Phase 3

    A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03387397, the US trial registry maintained by the National Library of Medicine. NCT03387397 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.